Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).


Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 12 09 2018
revised: 25 09 2018
accepted: 01 10 2018
pubmed: 28 11 2018
medline: 15 1 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

The International Collaboration on Cancer Reporting (ICCR) is a project which issues datasets and guidelines for international standardisation of cancer reporting. This review summarises the required and recommended elements of the datasets for prostate core needle biopsies and transurethral resection (TURP) and enucleation specimens of the prostate. To obtain as much information as possible from needle biopsies there should be only one core in each specimen jar with the exception of saturation biopsies. The gross description of the specimens should include core lengths of needle biopsies and weight of resection specimens. The tumours should be classified according to the 4th World Health Organization (WHO) classification and graded both by Gleason scores and the grouping of these in International Society of Urological Pathology (ISUP) grades (Grade groups). Percent high-grade cancer is an optional component of the report. Tumour extent in needle biopsies should be reported both by number of cores positive for cancer and the linear extent measured in either millimetre or percent core involvement by tumour. In needle biopsies where low-grade cancer is discontinuous and seen in few cores, it is recommended that the tumour extent should be reported both by including and subtracting intervening benign tissue. For resection specimens, the percentage of the tissue area (or percentage of number of TURP chips) involved with cancer should be estimated. Extraprostatic extension should be reported when seen, while the reporting of perineural, seminal vesicle/ejaculatory duct and lymphovascular invasion is only recommended. Intraductal carcinoma of the prostate (IDC-P) should be reported when present, because of its strong link with aggressive cancer. The current recommendation is that the IDC-P component should not be graded. The structured and standardised reporting of prostate cancer contributes to safer and more efficient patient care and facilitates the compilation and understanding of multiparametric diagnostic and prognostic data.

Identifiants

pubmed: 30477882
pii: S0031-3025(18)30481-1
doi: 10.1016/j.pathol.2018.10.003
pii:
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-20

Informations de copyright

Copyright © 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Auteurs

Lars Egevad (L)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: Lars.Egevad@ki.se.

Meagan Judge (M)

Royal College of Pathologists of Australasia, Sydney, NSW, Australia.

Brett Delahunt (B)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Peter A Humphrey (PA)

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.

Glen Kristiansen (G)

Institute of Pathology, University Hospital Bonn, Bonn, Germany.

Jon Oxley (J)

Department of Cellular Pathology, Southmead Hospital, Bristol, UK.

Krishan Rasiah (K)

Department of Urology, Royal North Shore Hospital, St Leonards, NSW, Australia.

Hiroyuki Takahashi (H)

Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan.

Kiril Trpkov (K)

Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Alberta, Canada.

Murali Varma (M)

Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.

Thomas M Wheeler (TM)

Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.

Ming Zhou (M)

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.

John R Srigley (JR)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

James G Kench (JG)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH